[dry] saxagliptin

Since the beginning of the year, the first good news of approval has come from the domestic pharmaceutical market According to statistics, in January, four of the eight varieties approved for marketing and deemed to have passed the consistency evaluation were the first generic drugs, which were lakosamide tablets (Jiangxi Qingfeng pharmaceutical industry), lamivudine tenofovir tablets (Anhui Baker Biology), sagletin tablets (osekang) and apixaban tablets (Jiangsu Haosen pharmaceutical industry) Among them, shagliptin, a black horse in the field of DPP-4 inhibitors, was approved for listing on January 21, adding new vitality to the diabetes generic market Catalog 1 Basic information 2 China registration application 3 Clinical trial 4 Listing approval 5 Market sale 6 Basic information of Drug Manual: sagletin (trade name onglyza) is a drug developed by Bristol Myers Squibb pharmaceutical company in the United States for the treatment of adult type II diabetes It was approved by FDA in March 2010, and approved by SFDA in May 2011 to enter the Chinese market It has the advantages of outstanding curative effect and long-lasting effect [ck02103] DPP-4 is an enzyme that breaks down the incretin, and shagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which can slow down the decomposition of increasing the level of these hormones in the body [ck020104], has become one of the main schemes of oral medication for type 2 diabetes Synthetic route 1 Synthetic Route 2 synthetic route 3 synthetic route 4 synthetic route 5 Synthetic Route 6 Synthetic Route 7 drug alias: bms-477118-11 original research unit: Bristol myerssquibb global highest status: approved for listing in 2010 ATC classification: A10bh03 digestive tract and metabolism > diabetes medication > non insulin hypoglycemic drugs > DPP-4 inhibitor target: DPP4; CYP3A4; ABCC1; CYP3A5; Slc22a8; Slco4c1 currently has only Merck sharp & dohmey Ltd imported medicine in China, Astra zenecaab imported medicine and the first generic medicine of Jiangsu aosaikang Pharmaceutical Co., Ltd., Novartis Europharm Ltd imported medicine and recently approved generic medicine of hausen and Qilu; Boehringer Ingelheim international only For the imported drugs of GmbH, only Takeda Pharmaceutical Company Limited imports agliptin China's registration, application, clinical trial, listing approval, China's listing approval, U.S listing approval, Japan's listing approval, Europe's listing approval, market and sales instructions for drugs (Article 9) data source: drug intelligence data Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.